Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix (NASDAQ: OCUL) announced its participation in three major scientific conferences in July and August 2025.

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) announced its participation in three major scientific conferences in July and August 2025. The company will present at the 8th Annual OIS Retina Innovation Summit, ASRS 2025 43rd Annual Scientific Meeting in Long Beach, CA, and Women in Ophthalmology (WIO 2025) in Amelia Island, Florida.

Key presentations will focus on the company's OTX-TKI (axitinib hydrogel) treatment for diabetic retinopathy, including data on retinal leakage assessment and macular fluid outcomes. Notable speakers include Chief Strategy Officer Sanjay Nayak, Chief Development Officer Peter K. Kaiser, and other medical experts.

Argus Session date unavailable

+0.30% session move Open Argus

Details

News Market Reaction – OCUL

The recorded move for OCUL in the trading session of this news was +0.30%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025.

8^th Annual OIS Retina Innovation Summit (OIS Retina 2025):
Long Beach, CA

• Company Presentation: Ocular Therapeutix
  

Session: Spotlight on Drug Delivery
Session Date/Time: Tuesday, July 29, 2025, 11:00 AM – 12:35 PM PT
Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer

• Panel Title: Spotlight on Drug Delivery
  

Session: Spotlight on Drug Delivery
Session Date/Time: Tuesday, July 29, 2025, 11:00 AM – 12:35 PM PT
Panelist: Peter K. Kaiser, MD, Chief Development Officer

The American Society of Retinal Specialists (ASRS 2025) 43^rd Annual Scientific Meeting:
Long Beach, CA

• Presentation Title: Longitudinal Quantitative Ultra-Widefield Retinal Leakage Assessment in Diabetic Retinopathy Following a Single Axitinib Hydrogel (OTX-TKI) in the HELIOS Trial
  

Session: Diabetic Retinopathy Symposium 2
Session Date/Time: Thursday, July 31, 2025, 11:35 AM – 12:15 PM PT
Presenter: Katherine Talcott, MD

• Poster Title: Macular Volumetric Fluid Outcomes Following Treatment with Intravitreal Axitinib Hydrogel (OTX-TKI) in Non-Proliferative Diabetic Retinopathy
  

Poster Date/Time: Thursday, July 31, 2025, 9:30 AM – 6:30 PM PT
Presenter: Devesh Kumar, MD

Women in Ophthalmology (WIO 2025):
Amelia Island, Florida

• Poster Title: Macular Fluid Volume and Retinal Vascular Leakage Analysis Following a Single Axitinib Intravitreal Hydrogel in Diabetic Retinopathy
  

Poster Date/Time: Saturday, August 9, 2025, 11 AM – 12 PM ET & Sunday, August 10, 2025, 9:45 AM – 10: 45 AM ET
Poster Location: Ballroom (Pre-Function)
Presenter: Diana Do, MD

Exact presentation times may be subject to change.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Explore the new corporate branding and follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Ocular Therapeutix (OCUL) present at the OIS Retina 2025 conference?

Ocular Therapeutix will present at the OIS Retina Innovation Summit in Long Beach, CA on Tuesday, July 29, 2025, from 11:00 AM to 12:35 PM PT.

What clinical data will OCUL present at the ASRS 2025 meeting?

At ASRS 2025, OCUL will present data on longitudinal quantitative ultra-widefield retinal leakage assessment in diabetic retinopathy following treatment with OTX-TKI, and macular volumetric fluid outcomes in non-proliferative diabetic retinopathy.

Who are the key presenters from Ocular Therapeutix at these conferences?

Key presenters include Sanjay Nayak (Chief Strategy Officer), Peter K. Kaiser (Chief Development Officer), Katherine Talcott, Devesh Kumar, and Diana Do.

What will be presented at the Women in Ophthalmology 2025 conference?

At WIO 2025, Dr. Diana Do will present a poster on macular fluid volume and retinal vascular leakage analysis following single axitinib intravitreal hydrogel treatment in diabetic retinopathy.